Resource Logo
CDC HIV/AIDS/Viral Hepatitis/STD/TB Prevention News Update

FDA Allows Large-Scale Trial of AIDS Vaccine


Wall Street Journal (06/03/98) P. B1

The Food and Drug Administration has awarded VaxGen permission to launch phase III trials of its Aidsvax AIDS vaccine candidate. The trial, which will last at least three years, will involve 5,000 subjects in the United States and 2,500 in Thailand. Some researchers--including Dr. David Baltimore, president of the California Institute of Technology--are skeptical about the vaccine, although phase I and II trials indicate that it induced measurable HIV antibodies in over 90 percent of those who received it. The vaccine candidate is designed to fight the two most common strains of HIV in the United States. Researchers who doubt the effectiveness of the vaccine candidate claim that it does not cause enough of an immune response. VaxGen is run by virologist Dr. Donald Francis, who also helped develop the gp120 AIDS vaccine--which was denied funding by the government after small-scale tests-- at Genentech. Dr. Anthony Fauci, head of the National Institute for Allergy and Infectious Diseases, noted that the new trial information is "interesting" and said that "if they have the resources to do it, there's a possibility that something can be learned."


Copyright © 1998 -CDC Prevention News Update, Publisher. All rights reserved to Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

Information in this article was accurate in June 3, 1998. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.